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Background: Antimicrobial resistance is increasing among clinical Campylobacter cases and is common among
isolates from other sources, specifically retail poultry - a major source of human infection. In this study the
antimicrobial susceptibility of isolates from a UK-wide survey of Campylobacter in retail poultry in 2001 and 2004–5
was investigated. The occurrence of phenotypes resistant to tetracycline, quinolones (ciprofloxacin and naladixic
acid), erythromycin, chloramphenicol and aminoglycosides was quantified. This was compared with a phylogeny for
these isolates based upon Multi Locus Sequence Typing (MLST) to investigate the pattern of antimicrobial
resistance acquisition.
Results: Antimicrobial resistance was present in all lineage clusters, but statistical testing showed a non-random
distribution. Erythromycin resistance was associated with Campylobacter coli. For all antimicrobials tested, resistant
isolates were distributed among relatively distant lineages indicative of widespread acquisition. There was also
evidence of clustering of resistance phenotypes within lineages; indicative of local expansion of resistant strains.
Conclusions: These results are consistent with the widespread acquisition of antimicrobial resistance among
chicken associated Campylobacter isolates, either through mutation or horizontal gene transfer, and the expansion
of these lineages as a proportion of the population. As Campylobacter are not known to multiply outside of the
host and long-term carriage in humans is extremely infrequent in industrialized countries, the most likely location
for the proliferation of resistant lineages is in farmed chickens.Background
Campylobacteriosis is a major public health problem and
is the most common bacterial cause of gastro-enteritis in
the industrialised world [1]. Campylobacter is a com-
mensal constituent in the microflora of a wide range of
animals, and has been isolated from numerous hosts in-
cluding domestic and wild mammals, birds and reptiles
[2-4]. In humans, however, Campylobacter is pathogenic,
routinely causing acute diarrhoea and occasionally serious
sequelae including Guillain-Barre Syndrome and reactive
arthritis [5]. The majority of human campylobacteriosis is* Correspondence: s.k.sheppard@swansea.ac.uk
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distribution, and reproduction in any mediumcaused by C. jejuni and C. coli [6]. Most cases are self-
limiting and do not require therapeutic intervention
but persistent or complicated cases and those affecting
immuno-compromised patients, require antimicrobial
treatment. Ciprofloxacin, a second generation fluoro-
quinolone, is commonly prescribed for the treatment of
diarrhoea, especially in returning travellers, while
macrolides are recommended where treatment is re-
quired for laboratory confirmed Campylobacter.
Since the late 1980′s there has been an observed in-
crease in the incidence of resistance to antimicrobials,
including fluoroquinolones and macrolides, in cases of hu-
man campylobacteriosis [7-11]. The development of resist-
ance is often attributed to inappropriate or incomplete
clinical usage of antimicrobials. However, this explanationentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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human cases are self-limiting and antimicrobial treatment
is unusual. Furthermore person-to-person transmission is
thought to be extremely rare in industrialised countries
therefore there would be little opportunity for resistant
lineages to proliferate [12]. With humans generally consid-
ered to be a dead-end host, there is a requirement to iden-
tify the most likely reservoirs for the acquisition of
antimicrobial resistance in Campylobacter.
Contaminated chicken meat is among the major
sources of Campylobacter associated with human dis-
ease. This has been demonstrated historically through
risk assessment [13], case–control studies [14] and out-
break investigation [15,16], and through the 1999 ‘dioxin
crisis’ natural experiment in Belgium, where all domes-
tically produced poultry meat was withdrawn from sale
and the incidence of human campylobacteriosis was re-
duced by 40% [17]. More recently attribution studies,
using MLST, have been used to compare genotypes of
Campylobacter strains carried by wild and farmed host
animals with those in human disease. This has shown a
link between strains found on chickens, retail poultry
and those causing disease in humans [18-21].
This study quantifies the occurrence of antimicrobial re-
sistance and investigates temporal trends among C. jejuni
and C. coli isolates from retail poultry. By considering this
in the context of a phylogeny for C. jejuni and C. coli, this
study was designed to investigate the extent to which
increases in antimicrobial resistance are the result of

























Figure 1 Proportion of resistant isolates for each antimicrobial. The p
isolates are indicated for samples collected as part of UK retail poultry surv
intervals, based on a binomial distribution (resistance: susceptibility) are giv
chloramphenicol (chl) and aminoglycosides (amino).Campylobacter lineages or (ii) clonal expansion of resist-
ant lineages. This provides evidence for the location and
nature of increased antimicrobial resistance among clinical
Campylobacter strains.
Results
Over the course of the study period a total of 194 STs,
belonging to 27 clonal complexes (CCs), plus a further
82 STs not assigned to any recognised clonal complex
were identified. Overall, the most abundant STs were ST
257 and ST 45, each representing 8.78% of the total
sample, ST 827 (3.89%), ST 51 (3.19%), ST 21 (2.99%)
and ST 573 (2.99%). There was no significant difference
in the proportions of dominant STs between the two
study periods.
Figure 1 presents the data for the percentage of resist-
ant isolates of both C. jejuni and C. coli between the first
phase of the study in 2001 and the second phase, in
2004–5. While there appears to be an increase in resist-
ance to all of the tested antimicrobials between the two
phases it was not possible to detect a statistically significant
secular trend with a sample of this size.
Overall, 38.02% (95% CI 35.01 – 41.02) C. jejuni and
C. coli isolates combined were resistant to tetracycline,
22.26% (95% CI 19.68 – 24.84) were resistant to
quinolones, 4.59% (95% CI 3.29 – 5.89) were resistant
to erythromycin, and 2.59% (95% CI 1.29 – 3.11) resistant
to chloramphenicol.
The genealogy estimated using CLONALFRAME,
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many of the lineages frequently identified from clinical
samples being represented. Isolate clustering on the tree
correlated with previously identified clonal complex des-
ignations (Table 1). For four (tetracycline, quinolones,
chloramphenicol & erythromycin) out of the five anti-
microbial substances tested in this study, resistance phe-
notypes were dispersed throughout clusters of related
lineages (Table 1). Nearly all isolates tested were sensi-
tive to aminoglycosides, therefore this class of antimicro-
bial agent was excluded from further analyses.Figure 2 ClonalFrame genealogies of Campylobacter isolates from UK
indicates the percentage of isolates in each ST with antimicrobial resistance
combined, (C) erythromycin, (D) chloramphenicol, (E) aminoglycosides. TheA total of 22 out of the 25 multi-ST lineages contained
isolates resistant to one or more antimicrobial. Tetracyc-
line resistant isolates were present in 20/25 clusters, with
the percentage of resistant isolates per cluster ranging
from 10% to 100%. Isolates resistant to quinolone were
present in 18/25 clusters and the proportion of resistant
isolates ranged from 10% to 90%. Chloramphenicol and
erythromycin resistant isolates were present in 11/25
and 8/25 clusters respectively and the proportion of re-
sistant isolates per cluster did not exceed 42.9% in chlor-
amphenicol or 25% in erythromycin.retail poultry surveys in 2001 and 2004–5. Grey-scale shading
to (A) tetracycline, (B) quinolones - naladixic acid & ciprofloxacin
scale bar indicates the genetic distance in coalescent units.
Table 1 Number and percentage of isolates from each lineage that tested resistant to each antimicrobial
Number and percentage (%) of tested isolates resistant to antimicrobial substance
LINEAGE (n) Dominant CC Tetracycline Quinolones3 Erythromycin Chloramphenicol Aminoglycosides
1 (209) 828 76 (36.4) 51 (24.40) 29 (13.88) 7 (3.35) 4 (1.91)
2 (187) 45 102 (54.55) 22 (11.76) 3 (1.60) 1 (0.53) 1 (0.53)
3 (131) 257 40 (30.53) 28 (21.37) 1 (0.76) 2 (1.53) 2 (1.53)
4 (44) 433 30 (68.18) 9 (20.45) 2 (4.55) 3 (6.82) 3 (6.82)
5 (21) 661 19 (90.48) 5 (23.81) 1 (4.76) 1 (4.76) 2 (9.52)
6 (16) 354 7 (43.75) 6 (37.50) 0 1 (6.25) 0
7 (7) 49 4 (57.14) 3 (42.86) 1 (14.29) 1 (14.29) 0
8 (5) 21 1 (20.00) 0 0 0 0
9 (35) 443 32 (91.43) 15 (42.86) 3 (8.57) 2 (8.57) 1 (2.86)
10 (5) 574 3 (60.00) 1 (20.00) 0 0 0
11 (8) 52 0 1 (12.50) 0 0 0
12 (3) 21 0 0 0 0 0
13 (11) 42 2 (18.18) 2 (18.18) 0 0 0
14 (12) 21 4 (33.33) 3 (25.00) 0 2 (16.67) 0
15 (21) 21 8 (38.10) 3 (14.29) 0 0 0
16 (3) 206 3 (100.00) 0 0 0 0
17 (4) 508 1 (25.00) 0 1 (25.00) 1 (25.00) 0
18 (10) 353 2 (20.00) 1 (10.00) 0 0 0
19 (10) 607 1 (10.00) 0 0 0 0
20 (7) 21 2 (28.57) 6 (85.71) 0 3 (42.86) 0
21 (4) 22 0 0 0 0 0
22 (7) 61 0 0 0 0 0
23 (10) 6 (60.00) 9 (90.00) 0 0 0
24 (3) 3 (100.00) 1 (33.33) 0 0 0
25 (2) 0 1 (50.00) 0 0 0
1 Lineages are defined as clusters of related genotypes based upon the ClonalFrame genealogy.
2 The clonal complex to which most of the STs belong.
3 Naladixic acid and ciprofloxacin.
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carried out to test the null hypothesis that populations
(species) are homogeneous in their resistance pheno-
types. In the case of tetracycline, quinolones and chlor-
amphenicol, p values > 0.1 were obtained, providing no
evidence to reject the null hypothesis. In the case of
erythromycin (p < 0.0005) there was a significant differ-
ence in the incidence of resistance between C. jejuni and
C. coli, with erythromycin resistance being associated
with C. coli (OR 6.52).
Further, permutation tests were carried out for each
antimicrobial, to test the null hypothesis that resistance
was randomly distributed throughout the C. jejuni line-
ages. There was statistical support for some association
between clade and probability of antimicrobial resist-
ance for tetracycline and quinolones (naladixic acid and
ciprofloxacin) in C. jejuni, although this is an in-
complete explanation in itself. For erythromycin andchloramphenicol no statistical support for an associ-
ation was identified (Figure 3).
Discussion
From the clinical perspective the observed prevalence of
resistance of C. jejuni and C. coli isolates to antimicro-
bial agents is high throughout the study period. These
findings are consistent with published data from clinical
Campylobacter isolates which show high levels of anti-
microbial resistance over a comparable time period [22]
and with other studies that show that antimicrobial re-
sistance patterns in clinical strains closely resemble
those observed in chicken meat isolates [23].
The high incidence of resistance to tetracycline in both
C. jejuni and C. coli indicates that this drug would be of
little use for the treatment of campylobacteriosis. In the
2004–5 study period the combined prevalence of quin-
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Figure 3 Permutation test results for the association of lineage with resistance phenotype for the tested antimicrobials. Comparison of
a measure of association of resistant lineages with that expected by chance for (A) tetracycline, (B) naladixic acid, (C) ciprofloxacin, (D) erythromycin,
(E) chloramphenicol. The arrows show the results from the data compared with frequency histograms of the scores from 10,000 permutations of the
data which show the expected distribution of scores if no association exists. No comparison was made for aminoglycosides because too few isolates
displayed resistance and so the test had no power.
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thromycin (currently recommended for the treatment of
laboratory-confirmed campylobacteriosis) resistance in
C. coli was 13.3% (28/210 samples). These levels of re-
sistance are likely to represent an unacceptable fre-
quency of therapeutic failure of the drugs indicated for
the treatment of human campylobacteriosis.
The high levels of antimicrobial resistance cannot be
accounted for exclusively by high numbers of a particular
group of resistant genotypes. Rather, there is evidence for
widespread acquisition of resistance among relatively dis-
tantly related lineages from retail poultry. This is consist-
ent with a small-scale study of C. jejuni isolated from
chicken meat in Senegal where quinolone resistant pheno-
types were present in three out of four tested lineages, and
also dispersed throughout singleton STs [24]. It is possible
that mutations that confer antimicrobial resistance have
occurred in multiple lineages. However, bacteria can ac-
quire genetic material, including antimicrobial resistance
genes, from relatively distantly related lineages through
horizontal gene transfer [25,26]. Horizontal Gene Transfer
(HGT) can involve recombination between lineages, oracquisition of plasmids, which has been demonstrated
to be the main mechanism of tetracycline resistance in
Campylobacter [27]. There is also evidence that plasmid
acquisition may mediate resistance to chloramphenicol
and aminoglycosides [28,29]. Resistance to macrolides
is conferred by a 2 bp change in the putative erythro-
mycin binding site. Resistance to fluoroquinolones is
most usually the result of a single mutation in the gyrA
region [30]. The widespread antimicrobial resistance in
the Campylobacter populations, is likely to be the result
of horizontal gene transfer as well as multiple independ-
ent mutation events.
When conditions are such that antimicrobial resist-
ance confers a strong selective advantage, lineages that
trace ancestry to resistant isolates will increase as a pro-
portion of the population [31]. Under these circum-
stances a phylogenetic tree will show clusters of resistant
lineages that have expanded clonally. Consistent with
this, statistical analyses of the CLONALFRAME tree of
retail poultry isolates indicated that resistant phenotypes
were not randomly distributed but showed some clus-
tering within lineages. At the highest level there was a
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ance correlated with C. coli, as in previous studies of
Campylobacter in pigs, turkeys and chickens [32-35].
Resistance to tetracycline, quinolones and chlorampheni-
col showed no association with either Campylobacter
species, but all were non-randomly distributed among
C. jejuni lineages. This could indicate that antimicrobial re-
sistance, having arisen in an ancestral lineage, is propagated
clonally by vertical transmission. This finding is consistent
with previous studies, in which associations were found be-
tween particular C. jejuni STs and serogroups, and a gyrA
gene mutation which is a putative mechanism of resistance
to quinolones [12].
For clonal expansion of resistant lineages to have oc-
curred among isolates from retail poultry requires that
strains had an opportunity to multiply. Mutation may
occur stochastically but persistence is influenced by the
fitness of organisms to compete in an environment
containing antimicrobials. Human campylobacteriosis is
self-limiting and person-to-person spread is thought to
be rare, therefore while the human gut may be an anti-
microbial rich environment, strains that acquire re-
sistance are not propagated and are lost from the
population. Retail poultry meat itself is an unlikely envir-
onment in which antimicrobial resistant strains increase
as a proportion of the population because Campylobacter
are not thought to multiply outside of the host. Isolates
from retail poultry essentially represent a subset of those
found in chickens on the farm and therefore resistance
among these strains is likely to reflect resistance patterns
among isolates inhabiting chicken guts [36,37].
Antimicrobials have historically been used in livestock
farming both for the treatment of infections and as
growth promoters. The practice of administering growth
promoters containing antimicrobials analogous to those
used in human medicine was banned in EU countries in
2003, and in 2006 the use of all antimicrobial growth
promoters was banned in the EU [http://www.vmd.gov.
uk/fsf/antimicrobial_agp.aspx]. However, specific antimi-
crobials are licensed for therapeutic use in poultry.
These include danofloxacin and difloxacin from the
quinolone and fluoroquinolone family, several tetracy-
clines, several macrolides (including two varieties
of erythromycin), and a number of aminoglycosides.
Amphenicols are not licensed for use in poultry farming
in the UK. Previous studies have speculated that where
flocks testing positive for Campylobacter and other in-
fections are treated en masse through the water supply
accurate dosing is impossible and an individual bird may
receive a dose too low to inhibit bacterial growth com-
pletely, thereby favouring antimicrobial resistant strains
[38]. Chickens may be considered a possible reservoir
in which antimicrobial resistant Campylobacter may
emerge. This has been shown in experimental conditionswhere resistance can be induced in Campylobacter-
colonised chicken flocks, following treatment with
fluoroquinolones [38,39].
Conclusions
The findings of this study suggest that antimicrobial re-
sistance in Campylobacter isolated from chicken meat is
widespread and may be increasing. Since retail poultry is
considered to be one of the most important reservoirs of
human Campylobacter infections, this pervasive resist-
ance is likely to have far-reaching public health conse-
quences. The diffuse pattern of resistance suggests that
horizontal gene transfer has a role in the acquisition of
resistance and evidence for the proliferation of resistant
lineage clusters indicates that conditions occur that
favour resistant strains – potentially on poultry farms.
As pressure to meet the demand for poultry has in-
creased there has been a requirement for greater intensi-
fication of farming practices. The consequences of this
are not fully understood but the trend towards increasing
levels of antimicrobial resistance among Campylobacter
isolates from retail poultry has implications for containing
outbreaks of drug resistant strains in humans.
Methods
Retail poultry survey isolates
Campylobacter isolates (n = 1002) were obtained from the
Health Protection Agency (HPA) Centre for Infections
archive, comprising isolates from three UK retail chicken
Campylobacter surveillance studies. Random, stratified
samples of 214, 535 and 253 isolates were drawn from the
National Retail Poultry Survey, April – June 2001; the Co-
ordinated Local Authority Sentinel Surveillance (CLASSP)
Study (2004–05); and Wales and Northern Ireland Sur-
veillance Study (2001–06), respectively [40-42]. In total,
214 isolates from 2001 and 788 from 2004–05 were
selected. The isolates represented both independent
butchers and large multiple outlet retail chains. 75% of all
isolates in the current study were of C. jejuni, and the re-
mainder were of C. coli, and the sample was stratified to
ensure that 50% of isolates were collected in England, and
the remaining 50% were divided evenly between Northern
Ireland, Scotland and Wales.
Culture
All Campylobacter strains had been stored in the archive
at −80°C in Microbank cryovials (Prolab PL1605/G)
prior to subculturing on Columbia Blood Agar (CBA).
Plates were incubated for 48 hours in a MACS-VA500
Variable Atmosphere Workstation (Don Whitley Scien-
tific Ltd) under microaerobic conditions (5% CO2, 5%
O2, 3% H2 and 87% N2) at 37°C. All microbiology proce-
dures were performed according to the standards of the
Clinical Pathology Accreditation (UK).
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All isolates were screened for antimicrobial susceptibility
(no growth) or resistance (growth) by the breakpoint
screening method [43]. Isolates were grown on Columbia
Blood Agar for 24 hours prior to suspension in distilled
water, with a density of bacterial cells equal to a
Macfarlands 0.5 standard for inoculation of antimicrobial
test plates. Individual antimicrobial substances tested were
incorporated into separate Iso-Sensitest Agar, enriched
with 5% horse blood, in the following concentrations:
chloramphenicol 8 μg/ml; gentamicin 4 μg/ml; kanamycin
16 μg/ml; neomycin 8 μg/ml; tetracycline 8 and 128 μg/ml;
nalidixic acid 16 μg/ml; ciprofloxacin 1 μg/ml; and
erythromycin 4 μg/ml. The concentration of ampicillin
tested changed from 32 μg/ml to 8 μg/ml during the
course of the retail poultry surveys, thus ampicillin resist-
ance was excluded from this study. A nationally or in-
ternationally recognised standard for the testing of
antimoicrobial sensitivities in Campylobacter does not
exist. The Campylobacter Reference Unit therefore devel-
oped and standardised a breakpoint method. While it dif-
fers from practices in some other laboratories it provides
consistency within this dataset.
DNA boilate preparation
Boilates for use as template in PCR reactions were pre-
pared as follows. A cell suspension of each culture was
made in 125 μl phosphate buffered saline or in water
(Sigma Aldrich, UK) in a 0.2 ml PCR tube. Suspensions
were vortexed and transferred to a heat block at 100°C
for five minutes. This killed cell suspension was clarified
by centrifugation at 13, 000 rpm for 10 min and stored
at −20°C.
PCR, Sequencing and bioinformatics
DNA template arrays were created in 96-well Thermo-
fast®, polypropylene plates (Abgene, UK) and seven-locus
MLST was carried out in Oxford by standard methods
using published primers [40,44]. Each 25 μl PCR reac-
tion comprised molecular grade water (Sigma-Aldrich,
United Kingdom), 2.5 μl 10x PCR buffer (Qiagen Ltd.),
0.25 μM each of forward and reverse primer, 0.2 mM
dNTP mix (Invitrogen Ltd.), 0.025 units/μl (0.125 μl) taq
polymerase (Qiagen Ltd.) and 2 μl of template DNA.
The PCR thermal cycle began with a 15 min denatur-
ation step at 95°C, followed by 35 cycles of 94°C for
30 seconds, 50°C for 30 seconds and 72°C for 1 minute,
with a final extension at 72°C for 5 minutes. 5 μl of PCR
products were visualised with ultraviolet transillumination
following electrophoresis at 200 V (10 min) on a 1%
(w/v) agarose gel in 1x TAE buffer (1 mM EDTA, 40 mM
Tris-acetate). The amplification products were puri-
fied by precipitation with 20% polyethylene glycol–
2.5 M NaCl [41] and stored at −20°C. Nucleotidesequencing PCRs were performed in both directions
with the same primers (f or r), diluted in water.
Reactions were carried out in 10 μl volumes containing
2 μl of PEG precipitated DNA resuspended in water,
1.0 μl 5x buffer, 0.02 μl BigDye Terminator v3.1 mix
(Applied Biosystems, UK) and 0.25 μM of either the
forward or the reverse primer. Cycling parameters
were as follows: 30 cycles of 96°C for 10 s, 50°C for
5 s, and 60°C for 2 min. Unincorporated dye termina-
tors were removed by precipitation of the termination
products with 95% ethanol, and the reaction products
were separated and detected with an ABI Prism 3730
automated DNA sequencer (Applied Biosyststems,
UK). Forward and reverse sequences were assembled
from the resultant chromatograms using the Staden
suite of computer programs from the Genetics Computer
Group package (Madison, WI). The consensus sequence
was queried against the Campylobacter database to give
an allele number. The combination of alleles for the
seven housekeeping genes gave the sequence type
(ST). STs are assigned into genetically related clonal
complexes, based on sharing four or more alleles with
the central genotype.
A database was developed in the framework provided
by the existing Campylobacter profiles database, [http://
pubmlst.org/Campylobacter/] which covers the species
C. jejuni and C. coli and is based on mlstdbNet software
[42]. The molecular data on this database includes
MLST and antigen sequence alleles.
Data analysis
A phylogeny was estimated from the study data using
ClonalFrame [45]. This model-based approach to deter-
mine bacterial microevolution distinguishes point muta-
tions from imported chromosomal recombination
events – the source of the majority of allelic polymor-
phisms. This allows more accurate estimation of clonal
relationships. A 75% consensus cut-off was imposed,
meaning that only branches identified in 75% or more
of the sampled trees were used in the final consensus
trees. The trees shown are consensus trees of 6
ClonalFrame runs each with a 1,000 burn in and 10,000
iterations. The strict parameters used to generate the
consensus trees ensured that cluster membership was
robustly supported.
Binomial exact 95% Confidence Intervals were calcu-
lated for the percentage of C. coli and C. jejuni isolates
resistant to each antimicrobial in the first and second
phases of the study to test for significant secular trends.
χ2 tests were carried out, to test for homogeneity of re-
sistance to each antimicrobial. The null hypothesis was
that populations (species) are homogeneous in their re-
sistance phenotypes. Permutation tests were then carried
out for each antimicrobial to test the null hypothesis
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microbial resistance phenotype within C. jejuni. Associ-
ation between antimicrobial resistance and lineage in the
observed data was summarised by an association score.
This score was calculated by adding the absolute values
for each lineage of the difference between the number of
resistant and the number of susceptible isolates in that
lineage. Resistance patterns were then randomised
across the dataset and an association score estimated for
this permuted dataset. This process was repeated 10,000
times and the observed score compared with the range
of scores obtained by permutation.
Competing interests
The authors declare that they have no competing interest.
Authors' contributions
The study was conceived and designed by SS, NM and MM. Sampling and
antimicrobial testing was carried out by JR, AL, RM, and CL. MLST was carried
out by SS. Analysis was performed by SS, HW, and NM. The paper was
written by HW, SS NM with contributions from the other authors. All authors
read and approved the final manuscript.
Acknowledgements
The authors would like to thank Florence Opesan, Olivia Coffey and Sophie
Rollinson -Food Standards Agency London for providing data, Keith Jolley
(University of Oxford) for help in creating the database, Robert Owens, Ella
Powell, Kate Martin, Hopi Yip and Radha Patel (Health Protection Agency,
Centre for Infections) for microbiological support and data provision, David
Lock (LACORS) and Ian Wilson (Northern Ireland Public Health Laboratory) for
survey coordination, and staff in a wide range of participating food control
laboratories (HPA, National Public Health Service - Wales and the Northern
Ireland Public Health Laboratory, Public Analysts). The Food Standards
Agency funded genotyping and analysis. SS is funded by a Wellcome Trust
Fellowship.
Author details
1Department of Zoology, University of Oxford, South Parks Road, Oxford OX1
3PS, UK. 2Gastrointestinal Bacteria Reference Unit, PHE Colindale, 61 Colindale
Avenue, NW9 5EQ, London, UK. 3School of Occupational & Public Health,
Ryerson University, 350 Victoria Street, Toronto M5B 2K3, Canada. 4Institute of
Life Science, College of Medicine, Swansea University, Swansea SA2 8PP, UK.
Received: 19 February 2013 Accepted: 10 July 2013
Published: 15 July 2013
References
1. Friedman CJ, Neiman J, Wegener HC, Tauxe RV: Epidemiology of
Campylobacter jejuni infections in the United States and other
industrialised nations. In Campylobacter. Edited by Nachamkin I, Blaser MJ.
Washington, D.C: ASM Press; 2000:121–138.
2. Broman T, Palmgren H, Bergstrom S, Sellin M, Waldenstrom J, Danielsson-
Tham ML, Olsen B: Campylobacter jejuni in black-headed gulls (Larus
ridibundus): prevalence, genotypes, and influence on C. jejuni
epidemiology. J Clin Microbiol 2002, 40:4594–4602.
3. Miller WG, Mandrell RE: Prevalence of Campylobacter in the Food and
Water supply: Incidence, Outbreaks, Isolation and Detection. In
Campylobacter: Molecular and Cellular Biology. Edited by Ketley JM, Konkel
ME. Poole UK: Horizon Bioscience; 2005:101–103.
4. Tu ZC, Zeitlin G, Gagner JP, Keo T, Hanna BA, Blaser MJ: Campylobacter
fetus of reptile origin as a human pathogen. J Clin Microbiol 2004,
42:4405–4407.
5. Zia S, Wareing D, Sutton C, Bolton E, Mitchell D, Goodacre JA: Health
problems following Campylobacter jejuni enteritis in a Lancashire
population. Rheumatology (Oxford) 2003, 42:1083–1088.
6. Gillespie IA, O'Brien SJ, Frost JA, Adak GK, Horby P, Swan AV, Painter MJ,
Neal KR, Collaborators CSSS: A case-case comparison of Campylobactercoli and Campylobacter jejuni infection: a tool for generating hypotheses.
Emerg Infect Dis 2002, 8:937–942.
7. Cody AJ, Clarke L, Bowler IC, Dingle KE: Ciprofloxacin-resistant
campylobacteriosis in the UK. Lancet 1987, 2010:376.
8. Reina J, Borrell N, Serra A: Emergence of resistance to erythromycin and
fluoroquinolones in thermotolerant Campylobacter strains isolated from
feces 1987–1991. Eur J Clin Microbiol Infect Dis 1992, 11:1163–1166.
9. Sanchez R, Fernandez-Baca V, Diaz MD, Munoz P, Rodriguez-Creixems M, Bouza
E: Evolution of susceptibilities of Campylobacter spp. to quinolones and
macrolides. Antimicrob Agents Chemother 1994, 38:1879–1882.
10. Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P: Trends in
antibiotic resistance among diarrheal pathogens isolated in Thailand
over 15 years. Clin Infect Dis 1998, 26:341–345.
11. Talsma E, Goettsch WG, Nieste HL, Schrijnemakers PM, Sprenger MJ:
Resistance in Campylobacter species: increased resistance to
fluoroquinolones and seasonal variation. Clin Infect Dis 1999, 29:845–848.
12. Endtz HP, Ruijs GJ, van Klingeren B, Jansen WH, van der Reyden T, Mouton
RP: Quinolone resistance in campylobacter isolated from man and
poultry following the introduction of fluoroquinolones in veterinary
medicine. J Antimicrob Chemother 1991, 27:199–208.
13. Friedman CR, Hoekstra RM, Samuel M, Marcus R, Bender J, Shiferaw B,
Reddy S, Ahuja SD, Helfrick DL, Hardnett F, et al: Risk factors for sporadic
Campylobacter infection in the United States: A case–control study in
FoodNet sites. Clin Infect Dis 2004, 38(Suppl 3):S285–296.
14. Neimann J, Engberg J, Molbak K, Wegener HC: A case–control study of risk
factors for sporadic Campylobacter infections in Denmark. Epidemiol Infect
2003, 130:353–366.
15. Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL: Epidemiology of
Escherichia coli O157:H7 outbreaks, United States, 1982–2002.
Emerg Infect Dis 2005, 11:603–609.
16. Olsen SJ, Patrick M, Hunter SB, Reddy V, Kornstein L, MacKenzie WR, Lane K,
Bidol S, Stoltman GA, Frye DM, et al: Multistate outbreak of Listeria
monocytogenes infection linked to delicatessen turkey meat.
Clin Infect Dis 2005, 40:962–967.
17. Vellinga A, Van Loock F: The dioxin crisis as experiment to determine
poultry-related Campylobacter enteritis. Emerg Infect Dis 2002, 8:19–22.
18. Sheppard SK, Dallas JF, Strachan NJ, MacRae M, McCarthy ND, Wilson DJ,
Gormley FJ, Falush D, Ogden ID, Maiden MC, Forbes KJ: Campylobacter
genotyping to determine the source of human infection. Clin Infect Dis
2009, 48:1072–1078.
19. Strachan NJ, Gormley FJ, Rotariu O, Ogden ID, Miller G, Dunn GM, Sheppard
SK, Dallas JF, Reid TM, Howie H, et al: Attribution of Campylobacter
infections in northeast Scotland to specific sources by use of multilocus
sequence typing. J Infect Dis 2009, 199:1205–1208.
20. Mullner P, Spencer SE, Wilson DJ, Jones G, Noble AD, Midwinter AC, Collins-
Emerson JM, Carter P, Hathaway S, French NP: Assigning the source of
human campylobacteriosis in New Zealand: A comparative genetic and
epidemiological approach. Infect Genet Evol 2009, 9:1311–1319.
21. Sheppard SK, dallas JF, Wilson DJ, Strachan NJ, mccarthy ND, Colles FM,
Rotariu O, Ogden ID, Forbes KJ, Maiden MCJ: Evolution of an agriculture-
associated disease causing Campylobacter coli clade: evidence from
national surveillance data in Scotland. In Book Evolution of an agriculture-
associated disease causing Campylobacter coli clade: evidence from national
surveillance data in Scotland. Cambridge, UK: PLoSone; 2010:e15708. vol. 5,
12 edition. pp. e15708 City.
22. Strachan NJC, Forbes KJ: The growing UK epidemic of human
campylobacteriosis. Lancet 2010, 376:665–667.
23. Gormley FJ, Strachan NJ, Reay K, MacKenzie FM, Ogden ID, Dallas JF, Forbes KJ:
Antimicrobial resistance profiles of Campylobacter from humans, retail
chicken meat, and cattle feces. Foodborne Pathog Dis 2010, 7:1129–1131.
24. Kinana AD, Cardinale E, Tall F, Bahsoun I, Sire JM, Garin B, Breurec S, Boye
CS, Perrier-Gros-Claude JD: Genetic diversity and quinolone resistance in
Campylobacter jejuni isolates from poultry in Senegal. Appl Environ
Microbiol 2006, 72:3309–3313.
25. Spratt BG: Hybrid penicillin-binding proteins in penicillin-resistant strains
of Neisseria gonorrhoeae. Nature 1988, 332:173–176.
26. Ochman H, Lawrence JG, Groisman EA: Lateral gene transfer and the
nature of bacterial innovation. Nature 2000, 405:299–304.
27. Taylor DE, Hiratsuka K, Ray H, Manavathu EK: Characterization and
expression of a cloned tetracycline resistance determinant from
Campylobacter jejuni plasmid pUA466. J Bacteriol 1987, 169:2984–2989.
Wimalarathna et al. BMC Microbiology 2013, 13:160 Page 9 of 9
http://www.biomedcentral.com/1471-2180/13/16028. Courvalin PM, Shaw WV, Jacob AE: Plasmid-mediated mechanisms of
resistance to aminoglycoside-aminocyclitol antibiotics and to
chloramphenicol in group D streptococci. Antimicrob Agents Chemother
1978, 13:716–725.
29. Wang Y, Taylor DE: Chloramphenicol resistance in Campylobacter coli:
nucleotide sequence, expression, and cloning vector construction.
Gene 1990, 94:23–28.
30. Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I:
Quinolone and macrolide resistance in Campylobacter jejuni and C. coli:
resistance mechanisms and trends in human isolates. Emerg Infect Dis
2001, 7:24–34.
31. Harris SR, Feil EJ, Holden MT, Quail MA, Nickerson EK, Chantratita N, Gardete
S, Tavares A, Day N, Lindsay JA, et al: Evolution of MRSA during hospital
transmission and intercontinental spread. Science 2010, 327:469–474.
32. Thakur S, Gebreyes WA: Campylobacter coli in swine production:
antimicrobial resistance mechanisms and molecular epidemiology.
J Clin Microbiol 2005, 43:5705–5714.
33. D'Lima CB, Miller WG, Mandrell RE, Wright SL, Siletzky RM, Carver DK,
Kathariou S: Clonal population structure and specific genotypes of
multidrug resistant Campylobacter coli from turkeys. Appl Environ
Microbiol 2007, 73:2156–2164.
34. Bywater RJ: Veterinary use of antimicrobials and emergence of resistance
in zoonotic and sentinel bacteria in the EU. J Vet Med B Infect Dis Vet
Public Health 2004, 51:361–363.
35. Wirz SE, Overesch G, Kuhnert P, Korczak BM: Genotype and antibiotic
resistance analyses of Campylobacter isolates from ceca and carcasses
of slaughtered broiler flocks. Appl Environ Microbiol 2010, 76:6377–6386.
36. Sheppard SK, Colles F, Richardson J, Cody AJ, Elson R, Lawson A, Brick G,
Meldrum R, Little CL, Owen RJ, et al: Host Association of Campylobacter
Genotypes Transcends Geographic Variation. Appl Environ Microbiol 2010,
76:5269–5277.
37. Hastings R, Colles FM, McCarthy ND, Maiden MC, Sheppard SK:
Campylobacter genotypes from poultry transportation crates indicate a
source of contamination and transmission. J Appl Microbiol 2011,
110:266–276.
38. McDermott PF, Bodeis SM, English LL, White DG, Walker RD, Zhao S, Simjee
S, Wagner DD: Ciprofloxacin resistance in Campylobacter jejuni evolves
rapidly in chickens treated with fluoroquinolones. J Infect Dis 2002,
185:837–840.
39. Jacobs-Reitsma WF, Kan CA, Bolder NM: The induction of quinolone
resistance in Campylobacter bacteria in broilers by quinolone treatment.
Lett Appl Microbiol 1994, 19:228–231.
40. Dingle KE, Colles FM, Falush D, Maiden MC: Sequence typing and
comparison of population biology of Campylobacter coli and
Campylobacter jejuni. J Clin Microbiol 2005, 43:340–347.
41. Embley TM: The linear PCR reaction: a simple and robust method for
sequencing amplified rRNA genes. Lett Appl Microbiol 1991, 13:171–174.
42. Jolley KA, Chan MS, Maiden MC: mlstdbNet - distributed multi-locus
sequence typing (MLST) databases. BMC Bioinforma 2004, 5:86.
43. Thwaites RT, Frost JA: Drug resistance in Campylobacter jejuni, C coli, and
C lari isolated from humans in north west England and Wales, 1997.
J Clin Pathol 1999, 52:812–814.
44. Miller WG, On SL, Wang G, Fontanoz S, Lastovica AJ, Mandrell RE: Extended
multilocus sequence typing system for Campylobacter coli, C. lari, C.
upsaliensis, and C. helveticus. J Clin Microbiol 2005, 43:2315–2329.
45. Didelot X, Falush D: Inference of bacterial microevolution using
multilocus sequence data. Genetics 2007, 175:1251–1266.
doi:10.1186/1471-2180-13-160
Cite this article as: Wimalarathna et al.: Widespread acquisition of
antimicrobial resistance among Campylobacter isolates from UK retail
poultry and evidence for clonal expansion of resistant lineages. BMC
Microbiology 2013 13:160.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
